Aditxt
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-09-01
- Employees
- 47
- Market Cap
- -
- Website
- http://www.aditxt.com
- Introduction
Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Richmond, VA.
Clinical Trials
1
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Immune Responses to COVID-19 Infection or Vaccination
- Conditions
- COVID-19
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Aditxt, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT05379478
- Locations
- 🇺🇸
Aditxt, Richmond, Virginia, United States
News
Adimune Advances ADI-100 Towards Clinical Trials for Multiple Autoimmune Diseases
Adimune has completed preclinical studies for ADI-100, demonstrating promising results in restoring immune tolerance for Type 1 Diabetes over a 10-month duration without compromising immune system function.
Persanta Advances Towards IPO with Dominari Securities to Commercialize Early Cancer Detection Technology
Persanta, an Aditxt subsidiary, has engaged Dominari Securities LLC as lead underwriter for its planned IPO targeted for the second half of 2025.
Appili Therapeutics Advances Pipeline with FDA-Approved Drug Launch and Vaccine Progress
Appili Therapeutics reported a net loss of $0.8 million in Q2 FY2025, an improvement from the previous year, and anticipates closing a take-private transaction with Aditxt in December 2024.
Appili Therapeutics Gains FDA Alignment on ATI-1801 Development for Leishmaniasis
Appili Therapeutics has received positive feedback from the FDA regarding its development strategy for ATI-1801, a topical antiparasitic product.
Appili Therapeutics Receives Positive FDA Feedback on ATI-1801 Development for NDA Submission
Appili Therapeutics announced that the FDA has provided positive feedback on its development strategy for ATI-1801, a topical antiparasitic product.